Maxit

Quick links to important sections

Maxit

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Maxit

Property Description
Active Ingredient Diclofenac (Potassium or Sodium Salt)
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Origin Synthetic Compound (Phenylacetic Acid Derivative)
Common Forms Oral Tablets, Topical Gels/Solutions
General Purpose Relief of Pain, Inflammation, and Fever

What Type of Medicine is Maxit?

Maxit is a commercial trade name for a medicine containing the active ingredient Diclofenac, which belongs to the class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Diclofenac is a synthetic compound, chemically categorized as a phenylacetic acid derivative. Maxit is often utilized for its rapid absorption characteristics, achieved by utilizing the potassium salt of Diclofenac, providing prompt symptomatic relief, such as easing acute discomfort.


Composition, Forms, and General Purpose

The efficacy of Maxit stems from Diclofenac, a single-ingredient product often formulated as the highly bioavailable potassium or sodium salt to influence the speed of drug absorption. This means the chemical composition is adjusted to help the body access the active compound quickly. Maxit is supplied in various dosage forms, including oral tablets, capsules, and topical gels or solutions, enabling administration via oral or topical routes. The medicine's general therapeutic purpose is to provide symptomatic relief for conditions characterized by pain, inflammation, or fever by reducing the production of specific prostaglandins—the local hormone-like substances responsible for signaling discomfort.

Regulatory References

  1. U.S. National Library of Medicine: MedlinePlus - Diclofenac

What side effects are possible with Maxit?

Possible Side Effects and Safety Information

The safety profile of Maxit (Diclofenac) is structured by regulatory bodies to categorize possible adverse reactions by frequency and affected physiological system. The most frequently documented events, classified as Common (occurring in 1% to 10% of users), include headache, dizziness, nausea, and other gastrointestinal disorders such as vomiting and dyspepsia.


Regulatory Classification of Adverse Reactions

Adverse reactions are officially listed across multiple System-Organ Classes (SOCs). The most prominent are Gastrointestinal disorders (ranging from common discomfort to rare serious events) and Nervous system disorders. Rare reactions (less than 1 in 1,000 users) include gastrointestinal haemorrhage, ulceration, and anaphylactic reactions.


Serious Safety Constraints

Regulatory warnings highlight the risk of Serious Adverse Reactions (SARs), which can be fatal. These include the potential for serious cardiovascular thrombotic events (such as myocardial infarction and stroke) and severe damage to the GI tract (bleeding and perforation). The risk of these SARs is officially stated to increase with higher doses and longer duration of use.


Population-Specific Safety Notes

The medicine is subject to specific regulatory constraints for certain populations. Maxit is contraindicated in the third trimester of pregnancy due to the risk of fetal cardiopulmonary toxicity. It is also contraindicated for use in the setting of Coronary Artery Bypass Graft (CABG) surgery pain, and in patients with known aspirin-sensitive asthma. Older adults are officially documented to have a greater absolute risk for serious gastrointestinal adverse events.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documentation for Maxit (Diclofenac) overdose focuses on specific clinical manifestations and mandated emergency actions. Overdose exposure may result in symptoms such as nausea, vomiting, stomach pain, headache, drowsiness, and ringing in the ears (tinnitus). These manifestations primarily affect the gastrointestinal system and the central nervous system.

In cases of severe intoxication, the official labeling cites life-threatening outcomes, including the risk of acute renal failure, liver failure, severe seizures, and coma. The potential for serious cardiovascular events, such as myocardial infarction and stroke, is also documented.

Immediate medical attention is mandated by regulatory authorities for any suspected overdose. Because no specific antidote is known, management is strictly symptomatic and supportive. This may involve administering activated charcoal to limit absorption and requires continuous monitoring of vital signs and diagnostic tests, such as an ECG and blood tests, during the emergency response phase. Patients with pre-existing conditions like renal or hepatic impairment face a higher risk of severe toxicity following overdose.

Therapeutic Uses of Maxit

Maxit (Diclofenac) is applied across key therapeutic domains where symptomatic relief from symptoms related to physical discomfort, inflammation, or systemic imbalance may be appropriate. It may provide support that helps ease the overall symptom burden.

Relief for Chronic Inflammatory Conditions

Maxit is commonly used for managing symptoms related to physical discomfort and functional limitations in conditions involving inflammatory or irritative processes, like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is applied in situations involving certain distressing symptoms, where it may assist in easing joint pain, stiffness, and swelling, offering symptomatic support that contributes to easing the overall symptom load.

Managing Acute Pain and Episodic Discomfort

The medication is relevant in contexts marked by increased discomfort where short-term symptomatic assistance is needed. This may assist in easing discomfort from acute musculoskeletal injuries like sprains and strains, as well as providing supportive relief during acute Migraine attacks and for the pain of primary Dysmenorrhea (menstrual cramps). It helps address symptom clusters that may become intense or disruptive and interfere with daily functioning. These uses cover the relief of associated tenderness, swelling, and stiffness.


Quick Fact: Relief for Joint Stiffness and Pain Maxit contributes to improved comfort and may assist with maintaining functional stability during symptomatic periods associated with inflammatory joint conditions.

Regulatory References

  1. Diclofenac: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Maxit eligibility is defined by official government documents through absolute prohibitions and required use restrictions. Most adults may use the medicine under standard conditions, and for certain formulations, use is established for pediatric patients 12 years of age and older. Conversely, use is generally not recommended for most children under 14 years and for women who are breastfeeding or attempting to conceive.

The medicine is contraindicated (must not be used) in patients with established severe cardiovascular disease, such as congestive heart failure (NYHA Class II-IV) or ischemic heart disease, and in those with active gastrointestinal bleeding or ulcers. It is also prohibited for individuals with a history of allergic-type reactions to aspirin or other NSAIDs, and for those recovering from Coronary Artery Bypass Graft (CABG) surgery. Maxit is absolutely prohibited in the last trimester of pregnancy (after 30 weeks gestation).

Populations with less severe organ impairment, such as mild to moderate hepatic or renal issues, may be eligible but are designated for conditional use only. Similarly, the elderly are an eligible population but must use the medicine with caution, as official labels require all at-risk patients to use the lowest effective dose for the shortest duration possible.

What should I know about interactions with other medicines?

Maxit Interactions with other medicines and products

Maxit (Diclofenac) interacts with several medicine classes and specific substances, often due to additive pharmacological effects or changes in drug concentration. This summary reflects officially documented interaction information from regulatory sources.

Contraindicated and High-Risk Combinations

The co-administration of Maxit is formally restricted or contraindicated with certain agents. These restrictions include using Maxit alongside other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including high-dose Aspirin used for pain relief, and other systemic diclofenac products like Ketorolac. The medicine is also restricted for use in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Interactions Affecting Systemic Exposure

Maxit is primarily metabolized by the CYP2C9 enzyme. Co-administration with strong CYP2C9 Inhibitors (e.g., Voriconazole) can significantly increase the plasma concentration (exposure) of Maxit. Conversely, Maxit reduces the clearance of certain co-administered drugs, leading to increased exposure of agents such as Lithium, Digoxin, and Methotrexate.

Pharmacodynamic and Systemic Risk

Co-administration with Anticoagulants (e.g., Warfarin) and Antiplatelet agents (including SSRIs) carries an officially documented increased risk of serious bleeding events. Maxit may also diminish the therapeutic effects of Diuretics and ACE Inhibitors/ARBs. This combination increases the official risk of deterioration of renal function, particularly in elderly and volume-depleted patients.

Substance and Timing Constraints

Due to the risk of reduced Maxit absorption, a mandatory separation of administration time is required when co-administering with Bile Acid Sequestrants (e.g., Colestipol). Maxit use should be restricted alongside alcohol due to an increased risk of gastrointestinal bleeding. Certain Maxit forms are officially advised to be taken without food.

Mechanism of Action

How Maxit Works

Maxit, containing Diclofenac, operates by a distinct biological strategy centered on inhibiting the synthesis of specific local hormone-like mediators. The drug's action is defined by three interconnected mechanistic domains that affect peripheral nociceptive pathways, the inflammatory cascade, and hypothalamic thermoregulation.


The core mechanism involves the competitive and reversible inhibition of the Cyclooxygenase (COX) enzymes, specifically the COX-1 and COX-2 subtypes. This molecular interaction blocks the crucial biochemical step required to produce prostaglandins—chemical mediators necessary for the development of local inflammatory signs. By suppressing this synthesis, the mechanism initiates a cascade that modifies the biochemical process underlying the inflammatory response at the tissue level.

This reduction of prostaglandins, particularly PGE2, directly impacts sensory nerve endings (nociceptors). Prostaglandins increase the sensitization of these nerves; removal of this signal raises the activation threshold of these neurons, which modifies the afferent nociceptive input originating from peripheral sites. The mechanism also extends to the hypothalamus, preventing a central prostaglandin increase that allows the thermal set-point to return to its basal state, resulting in the antipyretic physiological effect.

Dosage and Administration Information

Maxit is administered according to a structured protocol to ensure standardized delivery of the active ingredient, Diclofenac. The instructions specify approved routes, exact dosage ranges for different conditions, and conditions related to intake and duration.


Administration Scope

Feature Official Guideline
Route of Administration Oral (tablet, capsule, solution), Topical (gel, patch), Parenteral (IV, IM), and Rectal are officially approved routes.
Standard Adult Oral Dose For chronic conditions, such as Osteoarthritis, the daily dosage typically ranges from 100 mg to 150 mg, often given in divided doses. Maximum oral daily dosage is generally 150 mg for some indications, though up to 225 mg may be permitted for others.
Dosing Frequency Immediate-release forms are typically taken two to four times daily. Extended-release tablets are generally taken once per day. Acute treatments, such as for Migraine, utilize a single 50 mg dose.
Duration Principle Use is governed by the principle of utilizing the lowest effective dose for the shortest duration necessary for the individual’s treatment goals.

Procedural and Special Instructions

Instruction Type Requirement
Tablet Intake Delayed-release and extended-release oral tablets must be swallowed whole and must not be crushed, chewed, or split.
Preparation Powder for oral solution (e.g., 50 mg packets) must be mixed with 1 to 2 ounces of plain water only and consumed immediately.
Timing in Relation to Food While most oral forms can be taken without regard to food, the oral powder solution must be taken on an empty stomach.
Population Rule Specific dosage recommendations for pediatric patients are not established for most forms. For the elderly, it is recommended to initiate therapy with the lowest effective dose.

This collection of instructions defines the structured method by which the medicine is to be prepared and administered, setting the procedural foundation for its use across all approved routes and schedules.

Recent Clinical Evidence

Maxit: Recent Clinical Evidence

The body of evidence for Maxit (Diclofenac) originates from extensive clinical evaluation, primarily through numerous Randomized Controlled Trials (RCTs) and subsequent systematic reviews. The research focuses almost exclusively on symptomatic evaluation across several conditions.

Evidence for Chronic Symptom Management

Maxit has been examined in patient cohorts with chronic inflammatory conditions such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. Short-term RCTs monitored patient-reported outcomes, including changes in pain intensity, joint stiffness, and functional status scores. For inflammatory arthritic conditions, studies also tracked composite disease activity scores and joint counts. Research often involved monitoring patients concurrently using other long-term therapies.

Evidence for Acute and Episodic Pain

Research also examined Maxit in cohorts with acute and episodic pain, including acute musculoskeletal injuries (sprains/strains), Primary Dysmenorrhea, and Acute Migraine Attacks. Studies were typically short-term and placebo-controlled, focusing on rapid symptomatic measurements such as acute pain reduction and achieving a pain-free state within a few hours or days.

Limitations and Areas of Research Uncertainty

The research landscape highlights that Maxit was studied primarily for symptomatic evaluation. A key limitation is that most efficacy trials have limited follow-up durations, rarely extending beyond a few weeks or months. This means long-term effects on functional outcomes or disease progression are not fully established by the controlled evidence. Research relies on observational data for understanding long-term use patterns. Data for specific subgroups, such as individuals with significant comorbidities or highly severe disease manifestations, remain not as well characterized, and comparative evidence against all potential alternative treatments is often lacking.

Frequently Asked Questions (FAQ)

Common questions about Maxit (FAQ)


Q: Is it common to experience dizziness or drowsiness after taking Maxit?

A: Official product information and regulatory documents list dizziness and drowsiness (sleepiness) as potential side effects of the active ingredient in Maxit. Due to these potential effects, official guidance often advises caution when performing tasks that require alertness, such as driving.


Q: Can Maxit cause stomach upset, and is taking it with food necessary?

A: Gastrointestinal side effects such as nausea, vomiting, and indigestion have been reported with Maxit use. Official administration rules state that timing relative to food intake may vary based on the specific Maxit formulation (tablet, capsule, or oral solution).


Q: Does Maxit affect kidney function, especially if taken regularly?

A: Regulatory warnings note that long-term use of NSAIDs like Maxit may be associated with a risk of renal injury. Maxit's active ingredient is known to cause a dose-dependent reduction in blood flow to the kidneys, which is a key consideration for patients with pre-existing kidney conditions.


Q: What are the signs of an allergic reaction to Maxit that I should watch for?

A: Official warnings highlight the potential for serious allergic reactions. Signs may include difficulty breathing, wheezing, hives, or swelling of the face, lips, or throat. Maxit has also been associated with severe skin reactions, which can begin with symptoms like fever or a painful rash.


Q: Is it true that Maxit can sometimes mask the symptoms of an infection?

A: As an anti-inflammatory and fever-reducing drug, Maxit's active ingredient may mask the usual signs of fever and pain, which are common indicators of infection. This is a phenomenon recognized and noted in regulatory information regarding the use of this class of medicine.


Q: Does taking Maxit cause fluid retention or swelling?

A: Official documents state that fluid retention (edema) has been observed in some patients taking Maxit. For patients with a history of fluid retention or heart problems, official labels advise cautious use.


Q: Is the Diclofenac in Maxit primarily a COX-1 or COX-2 inhibitor?

A: The active ingredient in Maxit works by blocking the production of chemical messengers called prostaglandins through the inhibition of both the COX-1 and COX-2 enzymes. It is generally classified as a non-selective NSAID, meaning it acts on both types.


Q: Does Maxit affect fertility or ovulation?

A: Official information indicates that Maxit may cause a delay or prevent the rupture of ovarian follicles in some women. This effect has been associated with reversible infertility, and regulatory information indicates that women who are attempting to conceive may need to consider this factor.


Q: Is it normal to feel a mild headache when first starting Maxit?

A: Headache is listed in regulatory documents as a commonly reported side effect of Maxit. Although the official labeling does not specify the exact timing or severity, it is a known possible reaction.


Q: What should I do if a dose of Maxit causes unexpected nausea or vomiting?

A: Nausea and vomiting are listed as known common adverse effects associated with Maxit. Official regulatory guidance directs that any severe or persistent adverse reactions should be discussed with a healthcare provider.


Q: Are there specific storage instructions for Maxit to maintain its effectiveness?

A: Yes, official instructions require Maxit to be stored at a controlled room temperature and protected from excessive moisture and light. The medicine must be kept in its original, tightly closed container to maintain its stability and effectiveness.


Q: Has Maxit been subject to any recent significant safety warnings in the news?

A: Regulatory agencies continuously monitor the safety of medications and may issue advisories concerning the active ingredient in Maxit, particularly related to known cardiovascular and gastrointestinal risks. Patients can find the most current official information on regulatory websites.


Q: Is Maxit a suitable option for managing chronic conditions like arthritis?

A: Maxit's active ingredient is officially indicated for the management of the signs and symptoms of chronic inflammatory conditions, including osteoarthritis and rheumatoid arthritis. For chronic use, regulatory principles state that treatment should utilize the lowest effective dose for the shortest possible duration.


Q: What research is available on Maxit's use for migraines?

A: Specific Maxit formulations are indicated for the acute treatment of migraine attacks. This use is supported by findings from controlled clinical trials, as documented in official product information.


Q: Does Maxit have a sedative effect, making it difficult to drive?

A: Regulatory warnings state that the active ingredient in Maxit can cause central nervous system effects such as dizziness and drowsiness. Official labeling notes that due to these effects, caution is advised when performing tasks that require full alertness, such as driving or operating heavy machinery.


Q: Can Maxit be used to manage post-surgical pain?

A: Maxit is explicitly contraindicated (forbidden) for treating perioperative pain following Coronary Artery Bypass Graft (CABG) surgery. The regulatory status restricts its use in the setting of CABG surgery, while general use for other types of post-surgical pain is not specifically restricted.

How should Maxit be stored and disposed of?

How to Store and Dispose of Maxit?

The official labeling for Maxit (Diclofenac) requires specific storage and disposal procedures to maintain product stability and ensure public safety.


Storage Requirements

Maxit must be stored at controlled room temperature, typically ranging from 20 C to 25 C, with excursions up to 30 C permitted. The medicine must be kept from freezing and protected from excessive moisture and light. To maintain product integrity, the tablets should remain in the original container and the container must be kept tightly closed.

Child Safety and Disposal

It is officially mandated that Maxit must be stored out of the sight and reach of children.

For disposal, unused or expired Maxit should be returned through a formal drug take-back program or mail-back service. Regulatory guidance advises against discarding the medicine in wastewater (flushing down the toilet). If a take-back program is unavailable, the product should be mixed with an undesirable substance and sealed in a bag for safe disposal in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Maxit found in:

A-Z Index: